1.Percutaneous coronary intervention vs . medical therapy in patients on dialysis with coronary artery disease in China.
Enmin XIE ; Yaxin WU ; Zixiang YE ; Yong HE ; Hesong ZENG ; Jianfang LUO ; Mulei CHEN ; Wenyue PANG ; Yanmin XU ; Chuanyu GAO ; Xiaogang GUO ; Lin CAI ; Qingwei JI ; Yining YANG ; Di WU ; Yiqiang YUAN ; Jing WAN ; Yuliang MA ; Jun ZHANG ; Zhimin DU ; Qing YANG ; Jinsong CHENG ; Chunhua DING ; Xiang MA ; Chunlin YIN ; Zeyuan FAN ; Qiang TANG ; Yue LI ; Lihua SUN ; Chengzhi LU ; Jufang CHI ; Zhuhua YAO ; Yanxiang GAO ; Changan YU ; Jingyi REN ; Jingang ZHENG
Chinese Medical Journal 2025;138(3):301-310
BACKGROUND:
The available evidence regarding the benefits of percutaneous coronary intervention (PCI) on patients receiving dialysis with coronary artery disease (CAD) is limited and inconsistent. This study aimed to evaluate the association between PCI and clinical outcomes as compared with medical therapy alone in patients undergoing dialysis with CAD in China.
METHODS:
This multicenter, retrospective study was conducted in 30 tertiary medical centers across 12 provinces in China from January 2015 to June 2021 to include patients on dialysis with CAD. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Secondary outcomes included all-cause death, the individual components of MACE, and Bleeding Academic Research Consortium criteria types 2, 3, or 5 bleeding. Multivariable Cox proportional hazard models were used to assess the association between PCI and outcomes. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were performed to account for potential between-group differences.
RESULTS:
Of the 1146 patients on dialysis with significant CAD, 821 (71.6%) underwent PCI. After a median follow-up of 23.0 months, PCI was associated with a 43.0% significantly lower risk for MACE (33.9% [ n = 278] vs . 43.7% [ n = 142]; adjusted hazards ratio 0.57, 95% confidence interval 0.45-0.71), along with a slightly increased risk for bleeding outcomes that did not reach statistical significance (11.1% vs . 8.3%; adjusted hazards ratio 1.31, 95% confidence interval, 0.82-2.11). Furthermore, PCI was associated with a significant reduction in all-cause and cardiovascular mortalities. Subgroup analysis did not modify the association of PCI with patient outcomes. These primary findings were consistent across IPTW, PSM, and competing risk analyses.
CONCLUSION
This study indicated that PCI in patients on dialysis with CAD was significantly associated with lower MACE and mortality when comparing with those with medical therapy alone, albeit with a slightly increased risk for bleeding events that did not reach statistical significance.
Humans
;
Percutaneous Coronary Intervention/methods*
;
Male
;
Female
;
Coronary Artery Disease/drug therapy*
;
Retrospective Studies
;
Renal Dialysis/methods*
;
Middle Aged
;
Aged
;
China
;
Proportional Hazards Models
;
Treatment Outcome
2.Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study.
Yuequan SHI ; Xiaoyan LIU ; Anwen LIU ; Jian FANG ; Qingwei MENG ; Cuimin DING ; Bin AI ; Yangchun GU ; Cuiying ZHANG ; Chengzhi ZHOU ; Yan WANG ; Yongjie SHUI ; Siyuan YU ; Dongming ZHANG ; Jia LIU ; Haoran ZHANG ; Qing ZHOU ; Xiaoxing GAO ; Minjiang CHEN ; Jing ZHAO ; Wei ZHONG ; Yan XU ; Mengzhao WANG
Chinese Medical Journal 2025;138(14):1730-1740
BACKGROUND:
This study aimed to investigate programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in treating patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting.
METHODS:
This retrospective, multicenter, observational study enrolled adult patients who received PD-1/PD-L1 antibody-based therapy in China and met the following criteria: (1) had pathologically confirmed, unresectable stage III-IV NSCLC; (2) had a baseline PD-L1 tumor proportion score (TPS); and (3) had confirmed efficacy evaluation results after PD-1/PD-L1 treatment. Logistic regression, Kaplan-Meier analysis, and Cox regression were used to assess the progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAEs) as appropriate.
RESULTS:
A total of 409 patients, 65.0% ( n = 266) with a positive PD-L1 TPS (≥1%) and 32.8% ( n = 134) with PD-L1 TPS ≥50%, were included in this study. Cox regression confirmed that patients with a PD-L1 TPS ≥1% had significantly improved PFS (hazard ratio [HR] 0.747, 95% confidence interval [CI] 0.573-0.975, P = 0.032). A total of 160 (39.1%) patients experienced 206 irAEs, and 27 (6.6%) patients experienced 31 grade 3-5 irAEs. The organs most frequently associated with irAEs were the skin (52/409, 12.7%), thyroid (40/409, 9.8%), and lung (34/409, 8.3%). Multivariate logistic regression revealed that a PD-L1 TPS ≥1% (odds ratio [OR] 1.713, 95% CI 1.054-2.784, P = 0.030) was an independent risk factor for irAEs. Other risk factors for irAEs included pretreatment absolute lymphocyte count >2.5 × 10 9 /L (OR 3.772, 95% CI 1.377-10.329, P = 0.010) and pretreatment absolute eosinophil count >0.2 × 10 9 /L (OR 2.006, 95% CI 1.219-3.302, P = 0.006). Moreover, patients who developed irAEs demonstrated improved PFS (13.7 months vs. 8.4 months, P <0.001) and OS (28.0 months vs. 18.0 months, P = 0.007) compared with patients without irAEs.
CONCLUSIONS
A positive PD-L1 TPS (≥1%) was associated with improved PFS and an increased risk of irAEs in a real-world setting. The onset of irAEs was associated with improved PFS and OS in patients with advanced NSCLC receiving PD-1/PD-L1-based therapy.
Humans
;
Carcinoma, Non-Small-Cell Lung/metabolism*
;
Male
;
Female
;
Retrospective Studies
;
Middle Aged
;
Lung Neoplasms/metabolism*
;
Aged
;
B7-H1 Antigen/metabolism*
;
Programmed Cell Death 1 Receptor/metabolism*
;
Adult
;
Aged, 80 and over
;
Immune Checkpoint Inhibitors/therapeutic use*
3.Implementation and evaluation of OBE-based blended teaching methods in integrated curriculum
Qingwei ZHENG ; Shuxian GAO ; Li WEI
Journal of Shenyang Medical College 2025;27(2):216-219
Objective:To explore the implementation and effectiveness evaluation of an online-offline blended teaching method based on Outcome-Based Education(OBE)concept in integrated curriculum.Methods:A total of 28 students from Class 1 of the grade 2017 Information Management program,who underwent the traditional classroom teaching method before the reform of the Basic Medical Concepts course,were selected as the control group.Their evaluation was based on final exam scores(70%)and experimental scores(30%).In contrast,29 students from Class 1 of the grade 2019 Information Management program,who experienced the OBE teaching concept combined with online-offline blended teaching after the reform,were selected as the experimental group.Their evaluation included final exam scores(60%),experimental scores(20%),regular performance(10%),and online course performance(10%).The total scores,excellence rates,and course satisfaction were compared between the two groups.Result:The experimental group showed higher total scores,excellence rates,and course satisfaction compared to the control group(P<0.01).Conclusion:In the teaching of integrated curriculum,optimizing and integrating online resources and offline classroom teaching based on the OBE concept,reforming the teaching evaluation method,and forming a scientific and reasonable comprehensive evaluation system are important ways and measures to achieve better teaching results in blended teaching.
4.Research progress in early hepatic insufficiency after liver transplantation
Junhao PAN ; Yonghui GU ; Tao SHU ; Xiao GAO ; Qingwei WANG
Journal of Clinical Medicine in Practice 2025;29(13):128-131,136
Liver transplantation is an effective treatment for end-stage liver diseases,yet early al-lograft dysfunction(EAD)is commonly seen,and affects prognosis,thereby reducing graft and pa-tients' survival rates.Although an increasing number of patients benefit from liver transplantation,con-troversies persist regarding the associated factors and preventive strategies for EAD.This article re-viewed the research progress on liver transplantation both domestically and internationally,aiming to promote the development of liver transplantation surgery and improve treatment outcomes.
5.Clinical analysis of hypomethylating agent in preventing relapse after allogeneic hematopoietic stem cell transplantation in high-risk acute myeloid leukemia
Qingwei WANG ; Shengqin CHENG ; Bohan LI ; Li GAO ; Yanhua YAO ; Peifang XIAO ; Jun LU ; Jie LI ; Shaoyan HU
Chinese Journal of Pediatrics 2025;63(9):992-998
Objective:To explore the efficacy and feasibility of hypomethylating agent (HMA) as preventive therapy in children with high-risk acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Methods:A retrospective cohort study. Data from 173 children who underwent allo-HSCT for high-risk AML at Children′s Hospital of Soochow University between August 2019 and April 2023 were analyzed. Participants were categorized into a trial group receiving HMA and a control group. Further classification was based on HMA courses:≥4 and <4 courses. The efficacy and safety of HMA preventive treatment after allo-HSCT were evaluated. Survival analysis was performed using the Kaplan-Meier method with Log-Rank testing, the Fine-Gray model was used to assess cumulative relapse rates and Cox regression was used to identify prognostic factors. Adverse events during HMA were descriptively analyzed.Results:Among 173 patients, there were 100 males (57.8%) and 73 females (42.2%), with the age of 81 (34,127) months. The starting time of HMA was 123 (91, 191) d post-transplant, continuing 4.0 (3.0, 6.5) courses and the follow-up period was 24 (13, 32) months. The trial group (53 cases) showed better 2-year overall survival (OS) rate ((88.6±5.6)% vs. (76.6±4.3)%, χ 2=5.00, P=0.025) and relapse-free survival (RFS) rate ((89.2±4.7)% vs. (56.2±4.8)%, χ 2=15.75, P<0.001) than control group (120 cases). The 2-year OS rates and RFS rates were similar between ≥4 courses group (31 cases) and <4 courses group (22 cases)(both P>0.05). The cumulative relapse rate in the trial group was significantly lower ((10.8±0.2)% vs. (35.2±0.2)%, χ 2=10.84, P=0.001) than control group. Among children with molecular relapse, 8 cases (8/30, 26.7%) in the control group had hematological relapse compared to 1 case (1/2) in the trial group ( χ 2=0.81, P=0.369). The differences in incidence of acute and chronic graft-versus-host disease (GVHD) were not statistically significant (all P>0.05). Cox regression analysis revealed that minimal residual disease (MRD) positivity detected by flow cytometry before allo-HSCT and chronic GVHD were independent risk factors for OS (both P<0.05).The HMA preventive treatment was an independent protective factor for RFS, while age ≥10 years and MRD positivity detected by PCR before allo-HSCT were independent risk factors for RFS (all P<0.05). In trial group, 38 cases experienced grade 3 to 4 adverse events (71.7%). Conclusion:HMA is safe as preventive treatment in post-transplant children with high-risk AML, which can reduce the relapse risk and doesn't increase the risk of GVHD.
6.Implementation and evaluation of OBE-based blended teaching methods in integrated curriculum
Qingwei ZHENG ; Shuxian GAO ; Li WEI
Journal of Shenyang Medical College 2025;27(2):216-219
Objective:To explore the implementation and effectiveness evaluation of an online-offline blended teaching method based on Outcome-Based Education(OBE)concept in integrated curriculum.Methods:A total of 28 students from Class 1 of the grade 2017 Information Management program,who underwent the traditional classroom teaching method before the reform of the Basic Medical Concepts course,were selected as the control group.Their evaluation was based on final exam scores(70%)and experimental scores(30%).In contrast,29 students from Class 1 of the grade 2019 Information Management program,who experienced the OBE teaching concept combined with online-offline blended teaching after the reform,were selected as the experimental group.Their evaluation included final exam scores(60%),experimental scores(20%),regular performance(10%),and online course performance(10%).The total scores,excellence rates,and course satisfaction were compared between the two groups.Result:The experimental group showed higher total scores,excellence rates,and course satisfaction compared to the control group(P<0.01).Conclusion:In the teaching of integrated curriculum,optimizing and integrating online resources and offline classroom teaching based on the OBE concept,reforming the teaching evaluation method,and forming a scientific and reasonable comprehensive evaluation system are important ways and measures to achieve better teaching results in blended teaching.
7.Clinical analysis of hypomethylating agent in preventing relapse after allogeneic hematopoietic stem cell transplantation in high-risk acute myeloid leukemia
Qingwei WANG ; Shengqin CHENG ; Bohan LI ; Li GAO ; Yanhua YAO ; Peifang XIAO ; Jun LU ; Jie LI ; Shaoyan HU
Chinese Journal of Pediatrics 2025;63(9):992-998
Objective:To explore the efficacy and feasibility of hypomethylating agent (HMA) as preventive therapy in children with high-risk acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Methods:A retrospective cohort study. Data from 173 children who underwent allo-HSCT for high-risk AML at Children′s Hospital of Soochow University between August 2019 and April 2023 were analyzed. Participants were categorized into a trial group receiving HMA and a control group. Further classification was based on HMA courses:≥4 and <4 courses. The efficacy and safety of HMA preventive treatment after allo-HSCT were evaluated. Survival analysis was performed using the Kaplan-Meier method with Log-Rank testing, the Fine-Gray model was used to assess cumulative relapse rates and Cox regression was used to identify prognostic factors. Adverse events during HMA were descriptively analyzed.Results:Among 173 patients, there were 100 males (57.8%) and 73 females (42.2%), with the age of 81 (34,127) months. The starting time of HMA was 123 (91, 191) d post-transplant, continuing 4.0 (3.0, 6.5) courses and the follow-up period was 24 (13, 32) months. The trial group (53 cases) showed better 2-year overall survival (OS) rate ((88.6±5.6)% vs. (76.6±4.3)%, χ 2=5.00, P=0.025) and relapse-free survival (RFS) rate ((89.2±4.7)% vs. (56.2±4.8)%, χ 2=15.75, P<0.001) than control group (120 cases). The 2-year OS rates and RFS rates were similar between ≥4 courses group (31 cases) and <4 courses group (22 cases)(both P>0.05). The cumulative relapse rate in the trial group was significantly lower ((10.8±0.2)% vs. (35.2±0.2)%, χ 2=10.84, P=0.001) than control group. Among children with molecular relapse, 8 cases (8/30, 26.7%) in the control group had hematological relapse compared to 1 case (1/2) in the trial group ( χ 2=0.81, P=0.369). The differences in incidence of acute and chronic graft-versus-host disease (GVHD) were not statistically significant (all P>0.05). Cox regression analysis revealed that minimal residual disease (MRD) positivity detected by flow cytometry before allo-HSCT and chronic GVHD were independent risk factors for OS (both P<0.05).The HMA preventive treatment was an independent protective factor for RFS, while age ≥10 years and MRD positivity detected by PCR before allo-HSCT were independent risk factors for RFS (all P<0.05). In trial group, 38 cases experienced grade 3 to 4 adverse events (71.7%). Conclusion:HMA is safe as preventive treatment in post-transplant children with high-risk AML, which can reduce the relapse risk and doesn't increase the risk of GVHD.
8.Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer
Shuai HUANG ; Guihua SHENG ; Qiubo LV ; Ye LI ; Qingwei MENG ; Xuexiao GAO ; Zhiyuan SHANG
Journal of Gynecologic Oncology 2024;35(6):e100-
Objective:
Despite the availability of numerous treatment options, managing patients with platinum-resistant ovarian cancer (PROC) remains challenging, and the prognosis of PROC is notably unfavorable. This retrospective study aimed to assess the efficacy and safety of combined anlotinib-oral etoposide treatment for patients with PROC.
Methods:
Data of 23 patients who were diagnosed with PROC from January 2020 to November 2022 and treated with anlotinib combined with oral etoposide for at least 2 cycles were retrospectively analyzed.
Results:
Among per-protocol patients, 9 (45.0%; 95% confidence interval [CI]=21.1–68.9) of 20 patients achieved partial response and 17 (85.0%, 95% CI=67.9–100.0) of 20 patients achieved disease control. The median progression-free survival was 8.7 months (95% CI=5.3–11.6).The incidence of adverse events (any grade) was 100%, and the incidence of grade 3–4 adverse events was 54.5%.
Conclusion
Anlotinib combined with etoposide emerged effective for the treatment of PROC.
9.Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer
Shuai HUANG ; Guihua SHENG ; Qiubo LV ; Ye LI ; Qingwei MENG ; Xuexiao GAO ; Zhiyuan SHANG
Journal of Gynecologic Oncology 2024;35(6):e100-
Objective:
Despite the availability of numerous treatment options, managing patients with platinum-resistant ovarian cancer (PROC) remains challenging, and the prognosis of PROC is notably unfavorable. This retrospective study aimed to assess the efficacy and safety of combined anlotinib-oral etoposide treatment for patients with PROC.
Methods:
Data of 23 patients who were diagnosed with PROC from January 2020 to November 2022 and treated with anlotinib combined with oral etoposide for at least 2 cycles were retrospectively analyzed.
Results:
Among per-protocol patients, 9 (45.0%; 95% confidence interval [CI]=21.1–68.9) of 20 patients achieved partial response and 17 (85.0%, 95% CI=67.9–100.0) of 20 patients achieved disease control. The median progression-free survival was 8.7 months (95% CI=5.3–11.6).The incidence of adverse events (any grade) was 100%, and the incidence of grade 3–4 adverse events was 54.5%.
Conclusion
Anlotinib combined with etoposide emerged effective for the treatment of PROC.
10.Influence of different compressed sensing factors on susceptibility weighted imaging for displaying cerebral medullary vein
Jiajun CAO ; Jing YANG ; Yukun ZHANG ; Na LIU ; Bingbing GAO ; Yangyingqiu LIU ; Qingwei SONG ; Yanwei MIAO
Chinese Journal of Interventional Imaging and Therapy 2024;21(3):139-144
Objective To observe the influence of different acceleration factors(AF)on compressed sensing susceptibility weighted imaging(CS-SWI)for cerebral medullary veins of healthy people,and to screen the best AF.Methods Forty healthy volunteers were prospectively enrolled.Axial brain SWI images were obtained with CS technique under different AF(AF0,CS2,CS4,CS6,CS8 and CS10),and the phase value(PV)and standard deviation(SD)of bilateral septal vein(SV),internal cerebral vein(ICV),thalamus vein(TV),basal vein(BV)and dentate nucleus vein(DNV)were measured.Taken PV and SD of parietal white matter as controls,the signal-to-noise ratio(SNR)and contrast-to-noise ratio(CNR)of venous images were calculated.Then the original images were reconstructed with minimum intensity projection,and the subjective quality scoring of reconstructed images were performed using a 5-point scale.SNR,CNR,PV and quality score were compared among images under different AF,and the best AF,i.e.with the best performances for displaying and quantitatively analyzing cerebral medullary veins in healthy people was obtained.Results Compared with those acquired with AF0,SNR and CNR of all cerebral medullary veins acquired with CS6,CS8 and CS10 were significantly different(all adjusted P<0.05).Meanwhile,significant differences of PV in bilateral SV and right TV were found among CS6,CS8 and CS10,also in bilateral ICV,left TV and bilateral BV between CS8 and CS10(all adjusted P<0.05).Conclusion Excessive AF might decrease image quality of CS-SWI for cerebral medullary veins.CS4 was the best AF for displaying and quantitatively analyzing cerebral medullary veins in healthy people.

Result Analysis
Print
Save
E-mail